Vormatrigine Fails Primary Endpoint in Phase 2/3 Epilepsy Study; Program Paused
PRAX has more than doubled off its 52-week low of $36.3.
Summary
Praxis Precision Medicines announced that its vormatrigine drug candidate failed to meet the primary endpoint in a Phase 2/3 study for focal onset seizures, leading to a pause in further development for the program.
Key Events · Product Development and Regulatory · PRAX
-
Vormatrigine Study Fails Primary Endpoint
The Phase 2/3 POWER1 study evaluating vormatrigine in patients with focal onset seizures did not meet its primary success measure.
-
Future Study Paused
Enrollment in the follow-up POWER2 study has been paused to reassess the vormatrigine program and determine potential modifications.
-
Secondary Endpoint Met
The study did meet its secondary measure of a 50% response rate, and vormatrigine was generally well-tolerated with low discontinuations.
Analysis · PRAX · Life Sciences
This 8-K officially confirms the failure of vormatrigine to meet its primary endpoint in the Phase 2/3 POWER1 study for focal onset seizures, a significant setback for the company's pipeline. While secondary endpoints were met and the drug was well-tolerated, the primary failure leads to the pausing of the follow-up POWER2 study, indicating a re-evaluation of the program. This news, which was also reported by Wiseek News today, negatively impacts the company's drug development trajectory and future revenue potential from this candidate.
At the time of this filing, PRAX was trading at $285.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.3B. The 52-week trading range was $36.30 to $366.52. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.